Comparison · NCT02251041-sae
Combined Drug Approach vs Controles: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Combined Drug Approach vs Controles: serious adverse events. Trial comparisons, record NCT02251041-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02251041-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0787 | 0.319 | wilson | |
| Risk in group 2 | 0.111 | 0.0441 | 0.253 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0556 | -0.112 | 0.222 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.462 | 4.87 | log | |
| Odds ratio, group 1 over group 2 | 1.6 | 0.411 | 6.23 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Combined Drug Approach than on Controles | 18 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Combined Drug Approach | the group receives a combination of drugs~Antithrombin-III~Infliximab~Apotransferrin~Human recombinant erythropoietin~C1-Inhibitor~Glutathione~Alfa-tocopherol~Melatonin~Epoprostenol | 6 | 36 | EG000 |
| Group 2 | Controles | the group do not receive a combination of drugs, but a placebo (sodium chloride solution)~Sodium chloride solution | 4 | 36 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events were collected over the time frame of 1 year starting immediately after transplantation
Source ClinicalTrials.gov
Trial
- Title
- Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)
- NCT number
- NCT02251041
- Phases
- PHASE2
- Conditions
- Reperfusion Injury
- Interventions
- Antithrombin-III, Infliximab, Apotransferrin, Human recombinant erythropoietin, C1-Inhibitor, Glutathione, Alfa-tocopherol, Melatonin, Epoprostenol, Sodium chloride solution
- Lead sponsor
- Universitaire Ziekenhuizen KU Leuven
- Results first posted
- 2024-08-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02251041?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02251041-sae